HomeNewsWorldU.S. FDA advisers back COVID vaccines for children as young as 6 months

U.S. FDA advisers back COVID vaccines for children as young as 6 months

On Wednesday, a panel of FDA advisers unanimously recommended that the agency approve COVID-19 vaccinations from Moderna Inc and Pfizer Inc/BioNTech SE for millions of youngsters in the United States.

June 17, 2022 / 18:44 IST
Story continues below Advertisement

Advisers to the U.S Food and Drug Administration on Wednesday unanimously recommended the agency authorize COVID-19 vaccines from Moderna Inc (MRNA.O) and Pfizer Inc (PFE.N)/BioNTech SE (22UAy.DE) for millions of the youngest American children.

The committee's recommendation is an important step toward immunizing children under the age of 5 and as young as 6 months old who have not yet been eligible for the shots.

Story continues below Advertisement

The FDA is likely to authorize the shots soon. The U.S. government is planning for a June 21 start to its under-5 vaccination campaign should the vaccines receive FDA authorization, White House COVID-19 response coordinator Ashish Jha said last week.

COVID-19 is generally more mild in children than adults, but FDA officials told the panel that the number of U.S. COVID deaths so far in small children - roughly 442 under age 5 - "compared terribly" to the 78 deaths reported during the swine flu pandemic of 2019-2010.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show